EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN | Zendy

A. A. Ruleva | Zendy; С. М. Харит | Zendy; Е. П. Начарова | Zendy; I. V. Fridman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN

Author(s) -

A. A. Ruleva,

С. М. Харит,

Е. П. Начарова,

I. V. Fridman

Publication year - 2013

Publication title -

педиатрическая фармакология

Language(s) - English

Resource type - Journals

eISSN - 2500-3089

pISSN - 1727-5776

DOI - 10.15690/pf.v10i1.591

Subject(s) - group (periodic table) , medicine , chemistry , organic chemistry

The article is dedicated to the use of immunomodulators in children, conditions, at which the prescription of this group of drugs is reasonable, action mechanism and also efficacy are given. In particular, the authors give their observation results for a group of HPV-infected children vaccinated by live vaccines (rubella and divalent measles-parotitis vaccine) together with pidotimod usage. No undesirable phenomena were registered in the postvaccinal period. Dynamics of immunological indicators did not change significantly. Seroconversion level of measles antibodies totaled 100% by the 30 th observation day. Keywords : biologic response modifier therapy, HIV, live vaccines, children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research